Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Cellobiose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.54 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.46 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.46 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.46 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.59 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.59 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | AMY2A | P04746 | 3/20 | 0.53 |
| ▸ | TYR | P14679 | 2/20 | 0.49 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.49 |
| ▸ | GJA1 | P17302 | 1/20 | 0.48 |
| ▸ | GJB2 | P29033 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | IGF2R | P11717 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maltotriose SCHEMBL2377340 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL16786 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL373436 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL2229473 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Water SCHEMBL466158 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL19582547 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL373528 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL7072560 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL1308532 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Maltose SCHEMBL230121 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122042854-A | Application of indoleacetic acid in diagnosis and treatment of gestational diabetes mellitus | 中国医学科学院北京协和医院 | 2026-05-15 | — | — | CN | disclosed |
| US-12478612-B2 | Deuterated domperidone compositions, methods, and preparation | CINDOME PHARMA, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250332206-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF PROBIOTIC AND PREBIOTIC TO TREAT STUNTING | CHR. HANSEN A/S (DK) | 2025-10-30 | — | — | US | disclosed |
| EP-4637725-A1 | STABLE PHARMACEUTICAL COMPOSITION CONTAINING DAPAGLIFLOZIN AND SITAGLIPTIN AND PROCESS FOR THE PREPARATION THEREOF | Rontis Hellas S.A. (GR) | 2025-10-29 | — | — | EP | disclosed |
| EP-4608422-A1 | LACTIPLANTIBACILLUS PLANTARUM FOR USE IN ADDRESSING THE SYMPTOMS OF IRRITABLE BOWEL SYNDROME | Chr. Hansen A/S (DK) | 2025-09-03 | — | — | EP | disclosed |
| EP-3532028-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER AND METHOD FOR THE PREPARATION THEREOF | PHARMATHEN SA (GR) | 2025-08-20 | — | — | EP | disclosed |
| US-12331051-B2 | LSD derivatives, synthesis and method for treatment of diseases and disorders | BETTERLIFE PHARMA INC. (CA) | 2025-06-17 | — | — | US | disclosed |
| WO-2025121965-A1 | NOVEL CRYSTAL FORM OF TEGOPRAZAN SULFONIC ACID SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2025-06-12 | — | — | WO | disclosed |
| US-20250177320-A1 | PHARMACEUTICAL FORMULATIONS OF PHLOROGLUCINOL AND TRIMETHYLPHLOROGLUCINOL | CINRX PHARMA, LLC (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4548913-A1 | A MONOLAYER TABLET OF LINAGLIPTIN AND METFORMIN | Genepharm S.A. (GR) | 2025-05-07 | — | — | EP | disclosed |
| WO-2009001146-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ACETYLCHOLINE ESTERASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | GENEPHARM S.A. (GR) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009000286-A1 | IMPROVED PHARMACEUTICAL FORMULATION CONTAINING AN HMG-COA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | PARMATHEEN S.A. (GR) | 2008-12-31 | — | — | WO | disclosed |
| EP-1906931-B1 | IMPROVED PHARMACEUTICAL COMPOSITION CONTAINING ACE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | PHARMATHEN SA (GR) | 2008-12-03 | — | — | EP | disclosed |
| US-20080213356-A1 | Pharmaceutical Composition Containing Hmg-Coa Reductase Inhibitor And Method For The Preparation Thereof | PHARMATHEN S.A. (GR) | 2008-09-04 | — | — | US | disclosed |
| EP-1928425-A1 | PHARMACEUTICAL FORMULATION CONTAINING AN HMG-COA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Pharmathen S.A. (GR) | 2008-06-11 | — | — | EP | disclosed |
| EP-1924258-A1 | IMPROVED PHARMACEUTICAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Pharmathen S.A. (GR) | 2008-05-28 | — | — | EP | disclosed |
| EP-1906931-A1 | IMPROVED PHARMACEUTICAL COMPOSITION CONTAINING ACE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Pharmathen S.A. (GR) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007131517-A1 | PHARMACEUTICAL FORMULATION CONTAINING AN HMG-COA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | PHARMATHEN S.A. (GR) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007031801-A1 | IMPROVED PHARMACEUTICAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | PHARMATHEN S.A. (GR) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007003972-A1 | IMPROVED PHARMACEUTICAL COMPOSITION CONTAINING ACE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | PHARMATHEN S.A. (GR) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331051-B2 | LSD derivatives, synthesis and method for treatment of diseases and disorders | HTR4, SLC6A4, HRH4 | MEN1 2565/4885PTGS1 2894/4885PDE4A 1489/4885 |
| US-12478612-B2 | Deuterated domperidone compositions, methods, and preparation | DRD2, DRD1, DRD4 | MEN1 517/4885PTGS1 2418/4885PDE4A 194/4885 |
| US-20250177320-A1 | PHARMACEUTICAL FORMULATIONS OF PHLOROGLUCINOL AND TRIMETHYLPHLOROGLUCINOL | SLC5A2, SLC5A1, LCT | MEN1 528/4885PTGS1 2244/4885PDE4A 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.